Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients

Overview

This study investigated the use of novel plasma and urinary biomarkers to predicte the development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers investigated include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma BTP, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic patients who have or have not developed hepatorenal syndrome and compared between the two groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 2018

Detailed Description

This study investigated the use of novel plasma and urinary biomarkers to predicte the development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers tested include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma BTP, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic patients who have or have not developed hepatorenal syndrome and compared between the two groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome.

Arms, Groups and Cohorts

  • Hepatorenal syndrome group
    • Patients with advanced cirrhosis who develope hepatorenal syndrome
  • Non-hepatorenal syndrome group
    • Patients with advanced cirrhosis who do not hepatorenal syndrome

Clinical Trial Outcome Measures

Primary Measures

  • Hepatorenal syndrome
    • Time Frame: 12 weeks

Secondary Measures

  • Mortality
    • Time Frame: 6 months
  • Chronic renal impairment
    • Time Frame: 6 months

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with advanced cirrhosis (Child's B or C) referred for liver transplantation – Willing to give informed consent Exclusion Criteria:

  • Patients with co-existing renal diseases

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • The University of Hong Kong
  • Collaborator
    • The Hong Kong Society of Nephrology
  • Provider of Information About this Clinical Study
    • Principal Investigator: Dr. Desmond Yat-Hin Yap, Clinical Assistant Professor – The University of Hong Kong
  • Overall Official(s)
    • Desmond Yap, MD, Principal Investigator, The University of Hong Kong
  • Overall Contact(s)
    • Desmond Yap, MD, 85222553879, desmondy@hku.hk

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.